Atypical PKC: a target for treating insulin-resistant disorders of obesity, the metabolic syndrome and type 2 diabetes mellitus

Bibliography

• Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-69
   PubMed Web of Science ®Google Scholar
• Farese RV, Sajan MP, Wang H, et al. Muscle-specific knockout of PKC- lambda impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 2007;117:2289-301
   PubMedGoogle Scholar
• Sajan MP, Nimal S, Mastorides S, et al. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome and type 2 diabetes by inhibitors of hepatic protein kinase C-iota. Metab 2012;61:459-69
   PubMedGoogle Scholar
• Sajan MP, Ivy RA III, Lee MA, et al. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/Propeller/FYVE scaffold and is selectively inhibited by atypical PKC in early phases of diet-induced obesity: a mechanism for impairing gluconeogenic but not lipogenic enzyme expression. Diabetes 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Yang G, Badeaulou L, Bielawski J, et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009;297:E211-24
   PubMed Web of Science ®Google Scholar
• Ussher JR, Koves TR, Cadete VJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010;59:2453-64
   PubMed Web of Science ®Google Scholar
• Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 2011;121:4222-30
   PubMedGoogle Scholar
• Beeson M, Sajan MP, Dizon M, et al. Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance:amelioration by rosiglitazone and exercise. Diabetes 2003;52:1926-34
   PubMedGoogle Scholar
• Temofonte N, Sajan MP, Nimal S, et al. Combined thialidinedione-metformin treatment synergistically improves insulin signaling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinasse, atypical protein kinase C and protein kinase B/akt in human muscle. Diabetologia 2009;52:60-4
   PubMedGoogle Scholar
• Cusi K, Consoli A, DeFronzo R. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes. J Clin Endocrinol Metab 1996;81:4059-67
   PubMed Web of Science ®Google Scholar
• Luna V, Casauban L, Sajan MP, et al. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5- (PO4) in diabetic muscle. Diabetologia 2006;49:375-82
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-81
   PubMed Web of Science ®Google Scholar
• Stephenne X, Foretz M, Talcux N, et al. Metformin activates AMP-activated kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011;54:3101-10
   PubMed Web of Science ®Google Scholar
• Sajan MP, Ivy RA III, Farese RV. Meformin action in human hepatocytes: coactivation of atypical protein kinase C alters 5’-AMP-activated protein kinase effects on lipogenic and gluconeogenic enzyme expression. Diabetologia 2013;56:2507-16
   PubMedGoogle Scholar
• He L, Sabet A, Djedjos S, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009;15:635-46
   Google Scholar
• Standaert ML, Sajan MP, Miura A, et al. Insulin-induced activation of atypical protein kinase C, but not protein kinase B, is maintained in diabetic (ob/ob and Goto-Kakazaki) liver. Contrasting insulin signaling patterns in liver versus muscle define phenotypes of type 2 diabetic and high-fat-induced insulin-resistant states. J Biol Chem. 2004;279:24929-34
   Google Scholar
• Sajan MP, Standaert ML, Nimal S, et al. Critical role of atypical protein kinase C in activating hepatic SREBP-1c and NFkappaB in obesity. J Lipid Res 2009;50:1133-45
   PubMedGoogle Scholar
• Sajan MP, Farese RV. Insulin signalling in hepatocytes of type 2 diabetic humans. excessive expression and activity of PKC- iota and dependent processes and reversal by PKC-iota inhibitors. Diabetologia 2012;55:1446-57
   PubMedGoogle Scholar
• Farese RV, Sajan MP. Metabolic functions of atypical protein kinase C: “Good and Bad” as defined by nutritional status (invited review ) Am J Physiol Endocrinol Metab 2010;298:E385-94
   PubMedGoogle Scholar
• Guo S, Copps KD, Park S, et al. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 2009;29:5070-83
   PubMed Web of Science ®Google Scholar
• Sajan MP, Standaert ML, Rivas J, et al. Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NFkappaB) in liver of rodents used as model of diabetes, and relationships to hyperlipidaemia and insulin resistance. Diabetologia 2009;52:1197-207
   PubMed Web of Science ®Google Scholar
• Kitamura Y, Accilli D. New insights into the integrated physiology of insulin action. Rev Endocr Metab Disord 2004;5:143-9
   Google Scholar
• Matsumoto M, Pocal A, Rossetti L, et al. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor foxo1 in liver. Cell Metab 2007;6:208-16
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Ogawa W, Akimoto K, et al. PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 2003;112:935-44
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Kondo T, Sajan MP, et al. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta/. Cell Metab 2006;3:343-53
   PubMed Web of Science ®Google Scholar
• Fleischmann M, Iynedjian PB. Regulation of sterol regulatory element binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt. Biochem J 2000;349:13-17
   PubMed Web of Science ®Google Scholar
• Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010;107:3441-6
   PubMed Web of Science ®Google Scholar
• Cai DM, Yuan DF, Frantz PA, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-90
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Herrero L, Naaz A. Obesity, inflammation and insulin resistance. Gastroenterology 2007;132:2169-80
   PubMed Web of Science ®Google Scholar
• Kim Y-B, Kotani K, Ciaraldi TP, et al. Insulin-stimulated protein kinase C-lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes; reversal with weight reduction. Diabetes 2003;52:1935-42
   PubMed Web of Science ®Google Scholar
• Beeson M, Sajan MP, Gomez-Daspet J, et al. Defective activation of protein kinase C-zeta in muscle by insulin and phosphatidylinositol-3,4,5-(PO4)3 in obesity and polycystic ovary syndrome. Metab Syndr Relat Disord 2004;2:49-56
   PubMedGoogle Scholar
• Sajan MP, Ivey RA III, Lee M, et al. PKC lambda happloinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes. Mol Endocrinol 2014;28(7):1097-107
   PubMedGoogle Scholar